Cryoport reported second quarter 2026 total revenue of $49.0 million, an 8% increase year over year, and achieved positive adjusted EBITDA of $400,000, a $1.3 million improvement from the prior year. Life Science Services revenue grew 15% to $28.0 million, representing 57% of total revenue, while BioStorage/BioServices revenue rose 25% to $5.6 million. Commercial Cell and Gene Therapy revenue increased 9% to $9.4 million, with the services portion growing 26%, and CGT Clinical Trial revenue was up 12% to $13.4 million. The company affirmed its full-year 2026 revenue guidance of $192 million to $196 million, citing geopolitical and macroeconomic uncertainties as reasons for maintaining rather than raising the outlook. Cryoport supported 779 clinical trials globally, a net increase of 51 over the prior year, and 22 commercial therapies, including the recent FDA approval of TREGZI for client Orca Bio.
Cryoport IncAchieved positive adjusted EBITDA and 8% revenue growth, affirming guidance.
FDA approval of TREGZI for Orca Bio mentioned as a supported commercial therapy.
